


Form PTO-1449 for Courtesy Copies of References

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)



Docket Number 432722002612

Application Number 10/052,832

Applicant

Gregory R. MUNDY *et al.*

Filing Date January 15, 2002

Group Art Unit 1623

Hand Delivery Date February __, 2003

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.		09/096,631				June 12, 1998
RG	2.	8/1988	4,761,471	Urist	530	350	
	3.	1/1994	5,280,040	Labroo <i>et al.</i>	514	457	
	4.	12/1996	5,580,854	Orlowski <i>et al.</i>	514	18	
	5.	3/1998	5,728,844	Muller <i>et al.</i>	548	472	
	6.	6/1998	5,767,152	Nielsen <i>et al.</i>	514	526	
	7.	7/1998	5,780,454	Adams <i>et al.</i>	514	64	
	8.	10/1998	5,824,643	Pierce <i>et al.</i>	514	12	
	9.	6/1999	5,910,497	Durette <i>et al.</i>	514	253	
	10.	07/2000	6,083,690	Harris <i>et al.</i>	435	6	
	11.	11/2000	6,147,223	Fenteany <i>et al.</i>	548	453	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
RG	12.	10/1990	WO 90 11366	WIPO			
	13.	3/1992	WO 92 03125	WIPO			
	14.	10/1993	WO 93 20859	WIPO			
	15.	9/1995	WO 95 24211	WIPO			
	16.	9/1995	WO 95 25533	WIPO			
	17.	12/1996	WO 96 38590	WIPO			
	17.	3/1997	WO 97 09315	WIPO			
	18.	5/1997	WO 97 15308	WIPO			
	19.	05/1997	WO 97 18239	WIPO			
	20.	7/1997	WO 97 23457	WIPO			
	21.	10/1997	WO 97 38699	WIPO			
	22.	12/1997	WO 97 48694	WIPO			

EXAMINER:

RG. Tomen

DATE CONSIDERED:

8/22/03

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 for Courtesy Copies of References

Docket Number 432722002612

Application Number 10/052,832


Applicant

Gregory R. MUNDY *et al.*

Filing Date January 15, 2002

Group Art Unit 1623

Hand Delivery Date February __, 2003

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

23.	4/1998	WO 98 17267	WIPO					
24.	6/1998	WO 98 25460	WIPO					
25.	09/1999	WO 99 43346	WIPO					
26.	1/2000	WO 0002548	WIPO					
27.	10/1998	DE 197 16 713	Germany					
28.	7/1999	EP 0 931 544	Europe					
29.	4/1993	JP 05 097697	Japan					

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
RG	30.	Abu-Amer <i>et al.</i> , "NF-kB and Bone: The Breaking Point," NATURE MEDICINE (1997) 3(11):1189-1190
	31.	Adams, J. <i>et al.</i> , "Proteasome Inhibitors: A Novel Class of Potent and Effective Antitumor Agents," CANCER RES (1999) 59:2615-2622
	32.	Adams <i>et al.</i> , "Chapter 28. Novel Inhibitors of the Proteasome and their Therapeutic Use in Inflammation," ANNUAL REPORTS IN MEDICINAL CHEMISTRY (1996) 279-288
	33.	Ahmed <i>et al.</i> , "Alopecia Universalis Associated with a Mutation in the Human Hairless Gene," SCIENCE (1998) 279:720-724
	34.	Bangham <i>et al.</i> , "Diffusion of Univalent Ions Across the Lamellae of Swollen Phospholipids," J MOL BIOL (1965) 23:238-252
	35.	Barnes <i>et al.</i> , "Nuclear Factor -kB - A Pivotal Transcription Factor in Chronic Inflammatory Diseases," NEW ENGL J MED (1997) 336:1066-1071
	36.	Baumeister <i>et al.</i> , "The Proteasome: Paradigm of a Self-Compartmentalizing Protease," CELL (1998) 92:367-380
	37.	Beck <i>et al.</i> , "Rapid Publication TGF- β_1 Induces Bone Closure of Skull Defects," J BONE MINER RES (1991) 6(11):1257-1265
	38.	Bellows <i>et al.</i> , "Determination of the Capacity for Proliferation and Differentiation of Osteoprogenitor Cells in the Presence and Absence and Absence of Dexamethasone," DEVELOP BIOL (1990) 140:132-138
	39.	Blessing <i>et al.</i> , "Transgenic Mice as a Model to Study the Role of TGF- β -Related Molecules in Hair Follicles," GENES AND DEVELOP (1992) 7:204-215
	40.	Burgener <i>et al.</i> , "Fluoride Increase Tyrosine Kinase Activity in Osteoblast-like Cells: Regulatory Role for the Stimulation of Cell Proliferation and Pi Transport Across the Plasma Membrane," J

EXAMINER:

RGITOMEN

DATE CONSIDERED:

8/22/03

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 for Courtesy Copies of References

Docket Number 432722002612

Application Number 10/052,832

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Applicant

Gregory R. MUNDY *et al.*

Filing Date January 15, 2002

Group Art Unit 1623

Hand Delivery Date February __, 2003

BONE MINER RES (1995) 10:164-171

- 126 41. Caplan, "Mesenchymal Stem Cells" J ORTHOP RES (1991) 9:641-650
42. Casez *et al.*, "Dual-Energy X-Ray Absorptiometry for Measuring Total Bone Mineral Content in the Rat: Study of Accuracy and Precision," BONE AND MINER (1994) 26:61-68
43. Combaret, L. *et al.*, "Manipulation of the Ubiquitin-Proteasome Pathway in Cachexia: Pentoxifylline Suppresses the Activation of 20S and 26S Proteasomes in Muscles from Tumor-Bearing Rats," MOL BIOL REP (1999) 26:95-101
44. Coux, O. *et al.*, "Structure and Functions of the 20S and 26S Proteasomes," AN REVIEW BIOCHEM (1996) 65:801-847
45. Craiu, A. *et al.*, "Lactacystin and Clasto-Lactacystin β -Lactone Modify Multiple Proteasome β -Subunits and Inhibit Intracellular Protein Degradation and major Histocompatibility Complex Class I Antigen Presentation," J BIOL CHEM (1997) 272:13437-13445
46. Cui *et al.*, "Lovastatin Prevents Steroid-Induced Adipogenesis and Osteoporosis," ASBMR 18th Annual Meeting (September 1996) J BONE MINER RES (1996) 11(S1):S510
47. Ducy *et al.* "Increased Bone Formation in Osteocalcin-deficient Mice," NATURE (1996) 382:448-452
48. Edelman *et al.*, "Controlled and Modulated Release of Basic Fibroblast Growth Factor," BIOMATERIALS (1991) 12:619-626
49. Elofsson *et al.*, Chemistry & Biology (1999) 6:811-822
50. Ferretti, "Perspectives of pQct Technology Associated To Biomechanical Studies in Skeletal Research Employing Rat Models," BONE (1995) 17:353S-364S
51. Figueiredo-Pereira *et al.*, "A New Inhibitor of the Chymotrypsin-Like Activity of the Multicatalytic Proteinase Complex (20S Proteasome) Induces Accumulation of Ubiquitin-Protein Conjugates in a Neuronal Cell," J NEUROCHEM (1994) 63:1578-1581
52. Franzoso *et al.*, "Requirement for NF- κ B in Osteoclast and B-Cell Development," GENES AND DEV (1997) 11:3482-3496
53. Garrett *et al.*, "Specific Inhibitors of the Chymotryptic Component of the Proteasome are Potent Bone Anabolic Agents In Vivo" Journal of Bone and Mineral Research (2000) 15(Suppl.1):S197
54. Gat *et al.*, "De Novo Hair Follicle Morphogenesis and Hair Tumors in Mice Expressing a Truncated β -Catenin in Skin," CELL (1998) 95:605-614
55. Ghosh-Choudhery *et al.*, "Immortalized Murine Osteoblasts Derived from BMP 2-T-Antigen Expressing Transgenic Mice," ENDOCRINOLOGY (1996) 137:331-339
56. Gowan *et al.*, "Actions of Recombinant Interleukin 1, Interleukin 2, and Interferon- γ on Bone Resorption in Vitro," J IMMUNOL (1986) 136:2478-2482
57. Groll *et al.*, J. Am. Chem. Soc. (2000) 122:1237-1238

EXAMINER:

R. Gloman

DATE CONSIDERED:

8/22/03

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 for Courtesy Copies of References

Docket Number 432722002612

Application Number 10/052,832

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Applicant

Gregory R. MUNDY *et al.*

Filing Date January 15, 2002

Group Art Unit 1623

Hand Delivery Date February __, 2003

58. Guijarro *et al.* "Lovastatin Inhibits Lipopolysaccharide-induced NF-kB Activation in Human Mesangial Cells," NEPHROL DIAL TRANSPLANT (1996) 11:990-996
59. Gupta *et al.*, "Oral Cyclosporine for the Treatment of Alopecia Areata," J AMER ACAD OF DERMATOLOGY (1990) 22(2):242-250
60. Hardy *et al.*, "The Secret Life of the Hair Follicle," TRANS GENET (1992) 8:55-61
61. Harris *et al.* "Effects of Transforming Growth Factor β on Bone Nodule Formation and Expression of Bone Morphogenetic Protein 2, Osteocalcin, Osteopontin, Alkaline Phosphatase, and Type I Collagen mRNA in Long-Term Cultures of Fetal Rat Calvarial Osteoblasts," J BONE MINER RES (1994) 9:855-863
62. Hilt, W. *et al.*, "Proteasomes: Destruction as a Programme," TRANS BIOCHEM SCI (1996) 21:96-101.
63. Iotsova *et al.*, "Osteopetrosis in Mice Lacking NF-kB1 and NF-kB2," NATURE MED (1997) 3:1285-1289
64. Jensen, T.J. *et al.*, "Multiple Proteolytic Systems, Including the Proteasome, Contribute to CFTR Processing," CELL (1995) 83:129-135
65. Kamiya *et al.*, J. Derm. Sci. (1998) 17:54-60
66. Kim *et al.*, "Preparation of Multivesicular Liposomes," BIOCHIM BIOPHYS ACTA (1983) 728:339-348
67. Kimmel *et al.*, "The Effect of Recombinant Human (1-84) or Synthetic Human (1-34) Parathyroid Hormone on the Skeleton of Adult Osteopenic Ovariectomized Rats," ENDOCRINOLOGY (1993) 132:1577-1584
68. Ksander *et al.*, "Exogenous Transforming Growth Factor-Beta 2 Enhances Connective Tissue Formation and Wound Strength in Guinea Pig Dermal Wounds Healing by Secondary Intent," ANN SURG (1990) 211(3):288-294
69. Laval-Jeantet *et al.*, "Dual-Energy X-Ray Absorptiometry of the Calcaneus: Comparison with Vertebral Dual-Energy X-Ray Absorptiometry and Quantitative Computed Tomography," CALCIF TISSUE INTL (1995) 56:14-18
70. Law *et al.*, Mol. Cell Biol. (1992) 12:103-111
71. Leserman *et al.*, "Targeting to Cells of Fluorescent Liposomes Covalently Coupled With Monoclonal Antibody or Protein A," NATURE (1980) 288:602-604
72. Liptay *et al.*, "Inhibition of Nuclear Factor Kappa B and Induction of Apoptosis in T-Lymphocytes by Sulfasalazine," BR J PHARMACOL (1999) 128(7):1361-1369
73. Lutz, "Effects of Cyclosporin A on Hair," SKIN PHARMACOLOGY (1994) 7:101-104
74. Majeska *et al.*, "Maintenance of Parathyroid Hormone Response in Clonal Rat Osteosarcoma Lines," EXP CELL RES (1978) 111:465-467
75. Maupin-Furlow, J.A. *et al.*, "A Proteasome from the methanogenic Archaeon Methanosarcina

EXAMINER:

R. G. Vroman

DATE CONSIDERED:

8/22/03

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 for Courtesy Copies of References

Docket Number 432722002612

Application Number 10/052,832

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Applicant

Gregory R. MUNDY *et al.*

Filing Date January 15, 2002

Group Art Unit 1623

Hand Delivery Date February __, 2003

thermophila," J BIOL CHEM (1995) 270:28617-28622

- | | |
|-----|---|
| 76. | Mayer <i>et al.</i> , "Vesicles of Variable Sizes Produced by a Rapid Extrusion Procedure," BIOCHIM BIOPHYS ACTA (1986) 858:161-168 |
| 77. | Meng <i>et al.</i> , "Epoxomicin, a Potent and Selective Proteasome Inhibitor, Exhibits In Vivo Antiinflammatory Activity" Proceedings of the National Academy of Sciences of the United States (1999) 96(18):10403-10408 |
| 78. | Mundy <i>et al.</i> , Science (1999) 286:1946-1949 |
| 79. | Murray <i>et al.</i> , "The Ubiquitin-Proteasome System and Cellular Proliferation and Regulation in Osteoblastic Cells," EXPERIMENTAL CELL RESEARCH (1998) 242:460-469 |
| 80. | Olson <i>et al.</i> , "Preparation of Liposomes of Defined Size Distribution by Extrusion Through Polycarbonate Membranes," BIOCHIM BIOPHYS ACTA (1979) 557:9-23 |
| 81. | Orford <i>et al.</i> , "Serine Phosphorylation-Regulated Ubiquitination and Degradation of β -Catenin," J BIOL CHEM (1997) 272:24735-24738 |
| 82. | Ozaki <i>et al.</i> , "NF-kB Inhibitors Stimulate Apoptosis of Rabbit Mature Osteoclasts and Inhibit Bone Resorption by these Cells," FEBS LETTERS (1997) 410:297-300 |
| 83. | Pahl <i>et al.</i> , "The Immunosuppressive Fungal Metabolite Gliotoxin Specifically Inhibits Transcription Factor NF-kB," J EXP MED (1996) 183:1829-1840 |
| 84. | Patent Abstracts of Japan (August 12, 1993) 17:436 (C-1096) |
| 85. | Patent Abstracts of Japan (June 20, 1987) 11:193 (C-430) |
| 86. | Patent Abstracts of Japan (April 25, 1986) 10:112 (C-342) |
| 87. | Peters, J. "Proteasomes: Protein Degradation Machines of the Cell," TRENDS BIOCHEM SCI (1994) 19: 377-382 |
| 88. | Rickard <i>et al.</i> , "Induction of Rapid Osteoblast Differentiation in Rat Bone Marrow Stromal Cell Cultures by Dexamethasone and BMP-2," DEVELOP BIOL (1994) 161:218-228 |
| 89. | Sampath <i>et al.</i> , "Isolation of Osteogenin, an Extracellular Matrix-Associated, Bone-Inductive Protein, by Heparin Affinity Chromatography," PROC NATL ACAD SCI USA (1987) 84:7109-7113 |
| 90. | Sin, N. <i>et al.</i> , "Total Synthesis of the Potent Proteasome Inhibitor Epoxomicin: A Useful Tool for Understanding Proteasome Biology," BIORG MED CHEM LETT (1999) 9:2283-2288 |
| 91. | Szoka <i>et al.</i> , "Procedure for Preparation of Liposomes With Large Internal Aqueous Space and High Capture by Reverse-Phase Evaporation," PROC NATL ACAD SCI USA (1978) 75:4194-4198 |
| 92. | Tencer <i>et al.</i> , "The Effect of Local Controlled Release of Sodium Fluoride on the Stimulation of Bone Growth," J BIOMED MAT RES (1989) 23:571-589 |
| 93. | Vinitzky <i>et al.</i> , "Inhibition of the Proteolytic Activity of the Multicatalytic Proteinase Complex (Proteasome) by Substrate-Related Peptidyl Aldehydes," J BIOL CHEM. (1994) 269(47):29860-29866 |

EXAMINER:

RG itomen

DATE CONSIDERED:

8/22/03

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 for Courtesy Copies of References

Docket Number 432722002612

Application Number 10/052,832

Applicant

Gregory R. MUNDY *et al.*

Filing Date January 15, 2002

Group Art Unit 1623

Hand Delivery Date February __, 2003

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

- | | |
|-----|---|
| 94. | Wahl <i>et al.</i> , "Sulfasalazine: A Potent and Specific Inhibitor of Nuclear Factor Kappa B," J CLIN INVEST (1998) 101(5):1163-1174 |
| 95. | Wang <i>et al.</i> , "Lipid Clearing Agents in Steroid-Induced Osteoporosis," J FORMOS MED ASSOC (1995) 94:589-592 |
| 96. | Wojcik <i>et al.</i> , "Ubiquitin-Mediated Proteolysis Centers in HeLa Cells: Indication from Studies of an Inhibitor of the Chymotrypsin-Like Activity of the Proteasome," EUR J CELL BIOL (1996) 71:311-318 |
| 97. | Wozney, "The Bone Morphogenetic Protein Family as Osteogenesis," MOLEC REPROD DEV (1992) 32:160-167 |

EXAMINER:

RGITOMEN

DATE CONSIDERED:

8/22/03

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.